EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes

Marina M Burlá iD, Karina L Silva, Bárbara C Peixoto iD, Livia R Goes, Isaclaudia Azevedo-Quintanilha, Fernando A Bozza iD, Marcelo A Soares iD, Andreia C de Melo iD, Eugenio D Hottz, Patricia T Bozza, João P B Viola iD

Viruses · 02.07.2026 · 18 (7) · 733

DOI: 10.3390/v18070733 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, online erschienen am 02.07.2026. Verfasst von Marina M Burlá und 10 weiteren Autor:innen. Beteiligte Einrichtung: Program of Immunology and Tumor Biology, Brazilian National Cancer Institute (INCA), Rio de Janeiro 20231-050, RJ, Brazil. Hauptthemen laut MEDLINE: COVID-19, Neoplasms, Cytokines, Lymphocytes. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, CNPq.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with cancer are at increased risk of severe outcomes from COVID-19. Yet, the immunological determinants underlying this vulnerability remain incompletely understood, particularly in low- and middle-income settings. Moreover, the impact of the severe viral disease surge and its compensatory mechanisms, such as stressed myelopoiesis, on this population needs further elucidation. This study aims to characterize the cytokine and lymphocyte profiles of cancer patients with COVID-19, correlate these profiles with disease severity, and compare them to those of non-cancer patients with COVID-19. Plasma cytokine, chemokine, and growth factor levels were quantified using Luminex technology, and immune cell subsets were characterized by flow cytometry. A total of 67 patients were analyzed: 40 with cancer (26 mild cases and 14 severe cases) and 27 without cancer (12 mild cases and 15 severe cases). Clinical outcomes showed an 86% mortality rate in cancer patients due to severe COVID-19. This contrasted with a 3.8% mortality rate in cancer patients with mild COVID-19, all unrelated to the infection. Our findings revealed elevated CXCL10 (IP-10) and reduced MIF levels in cancer patients with COVID-19, distinguished by disease severity. Compared with that in cancer patients with mild COVID-19, the level of CXCL10 in cancer patients with severe COVID-19 was further elevated. Additionally, cancer patients with COVID-19 presented reduced CD3+ T lymphocytes, expansion of CD4+CD25+FoxP3+ regulatory cells and CD56BRIGHT NK cells, a shift from effector memory to central memory T-cells, and increased numbers of exhausted (PD-1+) T lymphocytes. In conclusion, our data suggest a distinct immunological profile observed in cancer patients with COVID-19. Especially in severe cases, viral surge-related suppressor cells and proinflammatory cytokines were accompanied by a compensatory immunosuppressive state, with decreased effector function and increased exhaustion. This may negatively impact clinical outcomes and highlight potential implications for the management of cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19NeoplasmsCytokinesLymphocytesHumansFemaleMaleMiddle AgedSeverity of Illness IndexAgedSARS-CoV-2AdultT-Lymphocytes, RegulatoryT-Cell ExhaustionKiller Cells, Natural

Stichwörter der Autor:innen

COVID-19CXCL10/IP-10MIFNK cellsT lymphocyteT-cell exhaustionTreg cellscancer

Substanzen

Cytokines

Autor:innen und Institutionen

  • Program of Immunology and Tumor Biology, Brazilian National Cancer Institute (INCA), Rio de Janeiro 20231-050, RJ, Brazil.
  • Faculty of Medicine, Institute of Medical Education (IDOMED), Rio de Janeiro 20071-004, RJ, Brazil.
  • Program of Genetics and Tumor Virology, Brazilian National Cancer Institute (INCA), Rio de Janeiro 20231-050, RJ, Brazil.
  • Department of Genetics and Molecular Biology, Federal University of Rio de Janeiro State (UNIRIO), Rio de Janeiro 20211-010, RJ, Brazil.
  • Laboratory of Immunopharmacology, Oswaldo Cruz Institute (IOC), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-361, RJ, Brazil.
  • Intensive Care Medicine Laboratory, National Institute of Infectiology (INI), Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro 21040-361, RJ, Brazil.

ORCID-Profile: Marina M Burlá, Bárbara C Peixoto, Fernando A Bozza, Marcelo A Soares, Andreia C de Melo, João P B Viola

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
  • CNPq
  • FAPERJ
  • CAPES

Zitieren

APA

Burlá, M. M., Silva, K. L., Peixoto, B. C., Goes, L. R., Azevedo-Quintanilha, I., Bozza, F. A., Soares, M. A., de Melo, A. C., Hottz, E. D., Bozza, P. T., & Viola, J. P. B. (2026). Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes. Viruses, 18(7), 733. https://doi.org/10.3390/v18070733

Vancouver

Burlá MM, Silva KL, Peixoto BC, Goes LR, Azevedo-Quintanilha I, Bozza FA, et al. Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes. Viruses. 2026;18(7):733. doi:10.3390/v18070733

BibTeX
@article{Burl2026,
  author = {Burlá, Marina M and Silva, Karina L and Peixoto, Bárbara C and Goes, Livia R and Azevedo-Quintanilha, Isaclaudia and Bozza, Fernando A and Soares, Marcelo A and de Melo, Andreia C and Hottz, Eugenio D and Bozza, Patricia T and Viola, João P B},
  title = {Cytokine and Lymphocyte Profiles in COVID-19 Patients with Cancer: Implications for Disease Severity and Clinical Outcomes},
  journal = {Viruses},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {733},
  doi = {10.3390/v18070733}
}
Kostenlos starten →